The risk of venous thrombosis during use of Qlaira (R).

The thrombogenicity of the dienogest/estradiolvalerate-containing oral contraceptive (Qlaira(R)).

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21448

Enrollment

Registered

2010-05-10

Start date

2010-05-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Veneuze trombose, venous thrombosis. Anticonceptie, contraception

Interventions

Use of Qlaira or Microgynon-30 during 3 cycles.

Eligibility

Inclusion criteria

Inclusion criteria: Competent women, 18-35 years with the wish to use an oral contraceptive (Qlaira or Microgynon-30).

Exclusion criteria

Exclusion criteria: 1. People who are legally incapable; 2. Contra-indications for the use of oral contraceptives as described by the WHO and Dutch Society of Gynaecologists; 3. Pregnancy in the three months before the trial; 4. Use of medication which can influence coagulation; 5. Chronic/acute illness.

Design outcomes

Primary

Measure	Time frame
Sex-Hormone Binding Globulin (SHBG) and Activated Protein C-resistance (APC-resistance).	—

Contacts

Public ContactM. Raps

Postbus 9600

m.raps@lumc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)